Company Overview and News

 
Trading ideas: Econpile, Destini, Sentoria, Dayang

2018-08-30 thestar.com.my
KUALA LUMPUR: Econpile Holdings Bhd , Destini Bhd , Sentoria Group Bhd and Dayang Enterprise Holdings Bhd are among the stocks to watch today, according to JF Apex Research.
4634 GMALY BSTHY 4715 GMALF 5253 5141 5213 2771 GEBHF

 
Econpile, Destini, Sentoria, Dayang Enterprise, Telekom Malaysia, Bumi Armada, CIMB, Taliworks, YTL Corp, Pos Malaysia, Genting Malaysia, UMW Holdings, PPB Group, Boustead Holdings and 7-Eleven

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): Based on corporate announcements and news flow today, stocks in focus on Monday (Aug 30) may include Econpile Holdings Bhd, Destini Bhd, Sentoria Group Bhd, Dayang Enterprise Holdings Bhd, Telekom Malaysia Bhd, Bumi Armada Bhd, CIMB Group Holdings Bhd, Taliworks Corp Bhd, YTL Corp Bhd, Pos Malaysia Bhd, Genting Malaysia Bhd, UMW Holdings Bhd, PPB Group Bhd, Boustead Holdings Bhd and 7-Eleven Malaysia Holdings Bhd.
BSTHY WLMIF BRDBF GMALF 4065 5253 5141 6742 5213 2771 CIMDF 5210 4634 GMALY WLMIY 1023 4588 4863 4715 YTLPF MYTEF BSMAF F34 1818

 
Sentoria bags two terraced home contracts worth RM124.8 mil

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): Property developer Sentoria Group Bhd has accepted two letters of awards worth a combined RM124.8 million from H.A. Properties Sdn Bhd to build terraced homes in Kuantan, Pahang.
5213

 
KLCI to halt ascend as U.S.-China trade war escalates

2018-07-11 theedgemarkets
KUALA LUMPUR (July 12): The FBM KLCI’s ascend could be halted today in line with the overnight slide at most global market as the U.S.-China trade war escalates with for tit-for-tat measures.
4456 5213 7253 9334

 
Sentoria, MCE, KESM, DNeX, G3 Global and Handal Resources

2018-07-11 theedgemarkets
KUALA LUMPUR (July 11): Based on corporate announcements and news flow today, stocks that may draw attention on Thursday (July 12) include: Sentoria, MCE, KESM, DNeX, G3 Global and Handal Resources.
4456 5213 7253 9334

 
Sentoria buys 150 acres of Morib land for RM20.25m

2018-07-11 theedgemarkets
KUALA LUMPUR(July 11): Sentoria Group Bhd has bought 150 acres of land in Morib, Kuala Langat in Selangor for RM20.25 million, to be used for development purposes.
BSMAF 5213 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...